Summary of Research: Pregnancy and Infant Outcomes in Multiple Sclerosis: Findings from the Global MAPLE-MS Pharmacovigilance Program

Neurology and Therapy 2026 Open access

Read full text
Authors: Kerstin Hellwig, Hugh H. Tilson, Sandra Thiel, Kathryn Ball, Joerg Seebeck, Muriel Danten, Nancy Dubois, Meritxell Sabidó
DOI: 10.1007/s40120-025-00867-y
Cited by: 0
References: 1

Abstract

Information on pregnancy and infant outcomes after cladribine tablets exposure is limited, as its use is not recommended during pregnancy. This is a summary of the original published article 'Pregnancy and infant outcomes in multiple sclerosis: findings from the Global MAPLE-MS Pharmacovigilance Program'. The primary outcome is the prevalence of major congenital anomalies (MCAs) in babies. Secondary outcomes include other pregnancy outcomes (live birth, elective termination, spontaneous abortion, ectopic pregnancy, and stillbirth).

Fields of Study & Subjects

Multiple Sclerosis Research Studies Pregnancy and Medication Impact Cancer Risks and Factors

Publication details

Journal / source
Neurology and Therapy
Volume
15
Issue
2
Pages
475–478
Publication date
10 January 2026
Language
EN